手术治疗局限性肾细胞癌的强化影像随访未改善复发后生存:欧洲多中心RECUR数据库结果
基于RECUR数据库纳入2006至2011年间8个欧洲国家12家中心收治的1612例接受治愈性治疗的非转移性肾细胞癌患者,其中336例出现复发。随访影像强度超过EAU指南推荐两倍以上并未与复发后总生存改善相关;每例复发后仍无瘤存活患者所需随访影像数为542,高危患者为697。
要点
- 随访影像频率超过EAU指南推荐两倍以上未改善复发后总生存。
- 复发后每例无瘤存活患者所需随访影像数为542,高危患者697。
- 横断面影像与常规影像分别用于47%和53%的复发检测。
核心结论
- 随访期间使用超过2017年EAU指南推荐的影像检查强度不太可能改善复发后总生存。
研究设计与样本
- 基于RECUR数据库的回顾性多中心研究,纳入2006至2011年间8个欧洲国家12家中心接受治愈性治疗的1612例非转移性肾细胞癌患者,其中336例复发。
主要发现
- 336例患者出现复发,横断面影像(CT、MRI)和常规影像(胸片、超声)分别用于47%和53%的复发检测。
- 随访影像强度超过EAU指南推荐两倍以上与复发后总生存改善无关。
- 每例复发后仍存活且无瘤证据的患者所需随访影像数为542,高危患者为697。
关键数值与推荐
- 强化影像随访定义为超过EAU指南推荐的两倍以上。
- 复发后每例无瘤存活患者所需随访影像数为542,高危患者为697。
临床怎么用
- 对于接受治愈性治疗的局限性肾细胞癌患者,随访影像频率不宜超过EAU指南推荐的两倍以上。
- 需开展前瞻性研究以设计未来最优随访策略。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal follow-up (FU) strategy for patients treated for localised renal cell carcinoma (RCC) remains unclear. Using the RECUR database, we studied imaging intensity utilised in contemporary FU to evaluate its association with outcome after detection of disease recurrence. Consecutive patients with nonmetastatic RCC (n=1612) treated with curative intent at 12 institutes across eight European countries between 2006 and 2011 were included. Recurrence occurred in 336 patients. Cross-sectional (computed tomography, magnetic resonance imaging) and conventional (chest X-ray, ultrasound) methods were used in 47% and 53%, respectively. More intensive FU imaging (more than twofold) than recommended by the European Association of Urology (EAU) was not associated with improved overall survival (OS) after recurrence. Overall, per patient treated for recurrence remaining alive with no evidence of disease, the number of FU images needed was 542, and 697 for high-risk patients. The study results suggest that use of more imaging during FU than that recommended in the 2017 EAU guidelines is unlikely to improve OS after recurrence. Prospective studies are needed to design optimal FU strategies for the future. PATIENT SUMMARY: After curative treatment for localised kidney cancer, follow-up is necessary to detect any recurrence. This study illustrates that increasing the imaging frequency during follow-up, even to double the number of follow-up imaging procedures recommended by the European Association of Urology guidelines, does not translate into improved survival for those with recurrence.
引用
- Dabestani S, Beisland C, Stewart GD, et al. Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). Eur Urol. 2018. PMID: 30318330. doi:10.1016/j.eururo.2018.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。